Key Takeaways
- • The UK Takeover Panel published consultation paper PCP 2026/1 on 9 July 2026, proposing miscellaneous amendments to the Takeover Code intended to clarify existing provisions, codify Panel Executive practice, and improve operational effectiveness, with responses due by 2 October 2026.
- • Acting-in-concert rules will be narrowed to focus on defensive concert parties between shareholders and company directors, specifically targeting reduction-restriction covenants and board-recommendation voting undertakings—changes that codify long-standing practice but require close review in lock-up and investment agreement negotiations.
- • Reverse takeover definition will expand to cover acquisitions requiring greater than 100% increase in voting equity share capital (extending beyond Code-to-Code transactions) and will trigger extended information-sharing obligations under Rule 21.3 to competing bidders, increasing disclosure burdens on target companies pursuing alternative transactions.
- • Technical updates include replacing outdated "UK multilateral trading facility" terminology with "UK primary MTF" (aligning to 2024 regulations), streamlining mandatory offer rules under Rule 9.1 by consolidating guidance into Practice Statement 26, and clarifying when frustrating action restrictions lapse following unequivocal rejection of an approach.
- • Post-offer restrictions on significant asset transactions will align with Rule 2.8 practice, preventing former offerors who made unqualified no-increase or acceleration statements from acquiring target assets for three months following bid withdrawal or lapse—a constraint bidders can mitigate by reserving flexibility in advance.
Summary
The UK Takeover Panel's 9 July 2026 consultation paper introduces eight categories of amendments designed to enhance clarity and codify established regulatory practice rather than fundamentally reshape substantive rules. The proposals address recurring transaction structures and advisory requirements across corporate control transactions, affecting bidders, listed companies, private capital investors, institutional shareholders, and activist investors.
The most operationally significant proposal addresses acting-in-concert determinations under Note 5 of the Code. The Panel proposes narrowing the definition to focus exclusively on agreements that restrict a shareholder from reducing its shareholding—codifying its "defensive" concert party concern. The revised framework distinguishes between reduction-restriction covenants (which normally trigger concert party treatment unless the shareholder retains freedom to accept an offer) and voting agreements on director appointments or removals. Critically, agreements preventing votes against director-supported resolutions or in favour of director-opposed resolutions will no longer trigger presumed concertedness. This distinction carries material implications for structuring lock-ups, investment agreements, and IPO voting undertakings, though it fundamentally reflects existing Panel practice.
The reverse takeover amendments broaden both the definition and information-sharing obligations. Extending the definition to any acquisition requiring greater than 100% increase in voting equity share capital covers acquisitions of non-Code entities, businesses, or assets—beyond historical Code-on-Code transactions. Simultaneously, the Panel proposes extending Rule 21.3 equality-of-information obligations to reverse takeovers (excluding those constituting formal offers or subject to Rule 9 waivers), requiring targets pursuing large defensive or alternative acquisitions to share counterparty information with competing bidders. The Panel acknowledges this generates additional disclosure burden but considers it justified by enhanced information parity.
Technical and clarifying amendments address Rule 2.6(c) put-up-or-shut-up deadline extensions, streamlining drafting while codifying the Panel's practice of normally consenting to board-requested extensions. Similarly, comprehensive revisions to the 18 Notes on Rule 9.1 simplify and reorganize guidance without altering substantive mandatory offer triggers; shareholder activism guidance consolidates into Practice Statement 26. Amendments to Rule 28.7 on investment research forecasts remove the requirement for offeree companies to remove connected analysts' forecasts at offer period commencement while requiring disclosure of connecting relationships in consensus forecasts—reducing compliance burden while maintaining market transparency.
Additional amendments clarify "fair and reasonable" opinion language on special deals and management incentives (now required to reference shareholder interests specifically), establish clearer timelines for when frustrating action restrictions lapse following unequivocal rejection of an approach (5.00 pm on day seven following rejection), and align post-lapse asset transaction restrictions with no-increase statement practice. Under revised Note 1(a) on Rule 35.1, former offerors making unqualified no-increase or acceleration statements forfeit normal consent to purchase significant target assets for three months post-lapse—a constraint bidders can preserve flexibility against by reserving rights ex ante. The Code Committee invites responses through 2 October 2026, after which the Panel will publish a response statement detailing final amendments.
The most operationally significant proposal addresses acting-in-concert determinations under Note 5 of the Code. The Panel proposes narrowing the definition to focus exclusively on agreements that restrict a shareholder from reducing its shareholding—codifying its "defensive" concert party concern. The revised framework distinguishes between reduction-restriction covenants (which normally trigger concert party treatment unless the shareholder retains freedom to accept an offer) and voting agreements on director appointments or removals. Critically, agreements preventing votes against director-supported resolutions or in favour of director-opposed resolutions will no longer trigger presumed concertedness. This distinction carries material implications for structuring lock-ups, investment agreements, and IPO voting undertakings, though it fundamentally reflects existing Panel practice.
The reverse takeover amendments broaden both the definition and information-sharing obligations. Extending the definition to any acquisition requiring greater than 100% increase in voting equity share capital covers acquisitions of non-Code entities, businesses, or assets—beyond historical Code-on-Code transactions. Simultaneously, the Panel proposes extending Rule 21.3 equality-of-information obligations to reverse takeovers (excluding those constituting formal offers or subject to Rule 9 waivers), requiring targets pursuing large defensive or alternative acquisitions to share counterparty information with competing bidders. The Panel acknowledges this generates additional disclosure burden but considers it justified by enhanced information parity.
Technical and clarifying amendments address Rule 2.6(c) put-up-or-shut-up deadline extensions, streamlining drafting while codifying the Panel's practice of normally consenting to board-requested extensions. Similarly, comprehensive revisions to the 18 Notes on Rule 9.1 simplify and reorganize guidance without altering substantive mandatory offer triggers; shareholder activism guidance consolidates into Practice Statement 26. Amendments to Rule 28.7 on investment research forecasts remove the requirement for offeree companies to remove connected analysts' forecasts at offer period commencement while requiring disclosure of connecting relationships in consensus forecasts—reducing compliance burden while maintaining market transparency.
Additional amendments clarify "fair and reasonable" opinion language on special deals and management incentives (now required to reference shareholder interests specifically), establish clearer timelines for when frustrating action restrictions lapse following unequivocal rejection of an approach (5.00 pm on day seven following rejection), and align post-lapse asset transaction restrictions with no-increase statement practice. Under revised Note 1(a) on Rule 35.1, former offerors making unqualified no-increase or acceleration statements forfeit normal consent to purchase significant target assets for three months post-lapse—a constraint bidders can preserve flexibility against by reserving rights ex ante. The Code Committee invites responses through 2 October 2026, after which the Panel will publish a response statement detailing final amendments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.